Area:
Genetics, Molecular Biology
We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the
NIH Research Portfolio Online Reporting Tools and the
NSF Award Database.
The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please
sign in and mark grants as correct or incorrect matches.
Sign in to see low-probability grants and correct any errors in linkage between grants and researchers.
High-probability grants
According to our matching algorithm, Zachary E. Stine is the likely recipient of the following grants.
Years |
Recipients |
Code |
Title / Keywords |
Matching score |
2013 — 2015 |
Stine, Zachary E |
F32Activity Code Description: To provide postdoctoral research training to individuals to broaden their scientific background and extend their potential for research in specified health-related areas. |
Understanding Glutaminase Alternative Splicing in Cancer Metabolism @ University of Pennsylvania
DESCRIPTION (provided by applicant): The goal of this project is to train Dr. Zachary Stine in the laboratory of Dr. Chi Van Dang at the University of Pennsylvania. A comprehensive training plan has been developed for Dr. Stine that will increase his expertise in the techniques and theories of cancer metabolism, develop his ability to effectively communicate his science, expand his network of collaborators, and prepare him for academic independence, the pursuit of funding and finding an academic position. This project will prepare Dr. Stine to become independent academic investigator focusing on the role of oncogenes and their targets on cancer metabolism. Background and aims: Cancer cell metabolism is reprogrammed to meet elevated metabolic needs, with many tumors overexpressing MYC becoming dependent on Glutamine metabolism. The potential therapeutic target Kidney type Glutaminase (GLS), which catalyzes the first step in the conversion of Glutamine to TCA cycle intermediate, is alternatively spliced to form two isoforms with different cellular localization (GAC and KGA). The impact of these isoforms on tumor progression and cancer metabolism is not well understood. Specific Aims: 1) Determine if the GAC isoform of GLS is required for growth of p493 cells due to its contributions to mitochondrial metabolism. 2) Define the requirement for the GAC isoform of Glutaminase for in vivo tumor growth. 3) Define the role of SFRS10 in MYC-controlled GLS alternative splicing. My preliminary studies indicate that the GLS isoform GAC is required for cancer cell growth. Metabolomics can give a global view of how Glutamine is used in metabolism. Altering GLS splicing to deplete GAC without downregulating total GLS mRNA, metabolomics will be used to determine the role of the GAC GLS isoform in cancer metabolism. It will also be determine if the GAC is required for xenograft tumor growth in vivo. The role of MYC control of GLS alternative splicing in metabolic reprogramming will be determined. Disease relevance: This proposal will provide insight into the role of glutaminase isoforms in cancer. Additionally, metabolic profiling will allow us to understand the metabolic impacts of the isoforms and will help us predict therapeutic response of to glutaminase inhibition based on isoform expression levels. This study will provide fundamental insights into the role of GLS isoforms in cancer metabolism in vitro and in vivo. In light of emerging splice modulation clinical trials, this is a valuable opportunity to explore anti-tumorigenic possibility of modulating GLS splicing in vivo. By altering GLS splicing in vivo, we may be able to reduce the side effects that arise from GLS inhibitors that target both isoforms.
|
0.946 |